Cost of ectopic pregnancy management: Surgery versus methotrexate

Mitchell D Creinin, A. E. Washington

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Objective: To estimate the potential annual cost savings of methotrexate (MTX) therapy for ectopic pregnancy (EP) at our institution and nationally. Design: Retrospective. Setting: San Francisco General Hospital. Patients: All patients treated for EP in 1991. Interventions: Medical records and billing statements were reviewed. Main Outcome Measures: Direct costs were determined from billing statements, and indirect costs were estimated based on published data. Potential annual national cost savings from MTX treatment were then extrapolated using national statistics on the incidence of EP. Results: Fifty EPs were treated with an average direct cost of $7,972 per case. Direct and indirect costs totaled >$500,000. Fifteen (30%) of the cases would have been eligible for MTX treatment with a resultant cost savings of >$160,000. The potential annual national cost savings would be in excess of $280 million. Conclusions: If preliminary findings suggesting the effectiveness of MTX as an alternative therapy for EP are confirmed, appropriate use of MTX will not only reduce morbidity but also the substantial cost.

Original languageEnglish (US)
Pages (from-to)963-969
Number of pages7
JournalFertility and Sterility
Volume60
Issue number6
StatePublished - 1993

Fingerprint

Ectopic Pregnancy
Methotrexate
Cost Savings
Costs and Cost Analysis
San Francisco
Complementary Therapies
General Hospitals
Medical Records
Therapeutics
Outcome Assessment (Health Care)
Morbidity
Incidence

Keywords

  • cost
  • Ectopic pregnancy
  • methotrexate

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Cost of ectopic pregnancy management : Surgery versus methotrexate. / Creinin, Mitchell D; Washington, A. E.

In: Fertility and Sterility, Vol. 60, No. 6, 1993, p. 963-969.

Research output: Contribution to journalArticle

@article{f05f090cb703409f8d500a0b3bad1b06,
title = "Cost of ectopic pregnancy management: Surgery versus methotrexate",
abstract = "Objective: To estimate the potential annual cost savings of methotrexate (MTX) therapy for ectopic pregnancy (EP) at our institution and nationally. Design: Retrospective. Setting: San Francisco General Hospital. Patients: All patients treated for EP in 1991. Interventions: Medical records and billing statements were reviewed. Main Outcome Measures: Direct costs were determined from billing statements, and indirect costs were estimated based on published data. Potential annual national cost savings from MTX treatment were then extrapolated using national statistics on the incidence of EP. Results: Fifty EPs were treated with an average direct cost of $7,972 per case. Direct and indirect costs totaled >$500,000. Fifteen (30{\%}) of the cases would have been eligible for MTX treatment with a resultant cost savings of >$160,000. The potential annual national cost savings would be in excess of $280 million. Conclusions: If preliminary findings suggesting the effectiveness of MTX as an alternative therapy for EP are confirmed, appropriate use of MTX will not only reduce morbidity but also the substantial cost.",
keywords = "cost, Ectopic pregnancy, methotrexate",
author = "Creinin, {Mitchell D} and Washington, {A. E.}",
year = "1993",
language = "English (US)",
volume = "60",
pages = "963--969",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Cost of ectopic pregnancy management

T2 - Surgery versus methotrexate

AU - Creinin, Mitchell D

AU - Washington, A. E.

PY - 1993

Y1 - 1993

N2 - Objective: To estimate the potential annual cost savings of methotrexate (MTX) therapy for ectopic pregnancy (EP) at our institution and nationally. Design: Retrospective. Setting: San Francisco General Hospital. Patients: All patients treated for EP in 1991. Interventions: Medical records and billing statements were reviewed. Main Outcome Measures: Direct costs were determined from billing statements, and indirect costs were estimated based on published data. Potential annual national cost savings from MTX treatment were then extrapolated using national statistics on the incidence of EP. Results: Fifty EPs were treated with an average direct cost of $7,972 per case. Direct and indirect costs totaled >$500,000. Fifteen (30%) of the cases would have been eligible for MTX treatment with a resultant cost savings of >$160,000. The potential annual national cost savings would be in excess of $280 million. Conclusions: If preliminary findings suggesting the effectiveness of MTX as an alternative therapy for EP are confirmed, appropriate use of MTX will not only reduce morbidity but also the substantial cost.

AB - Objective: To estimate the potential annual cost savings of methotrexate (MTX) therapy for ectopic pregnancy (EP) at our institution and nationally. Design: Retrospective. Setting: San Francisco General Hospital. Patients: All patients treated for EP in 1991. Interventions: Medical records and billing statements were reviewed. Main Outcome Measures: Direct costs were determined from billing statements, and indirect costs were estimated based on published data. Potential annual national cost savings from MTX treatment were then extrapolated using national statistics on the incidence of EP. Results: Fifty EPs were treated with an average direct cost of $7,972 per case. Direct and indirect costs totaled >$500,000. Fifteen (30%) of the cases would have been eligible for MTX treatment with a resultant cost savings of >$160,000. The potential annual national cost savings would be in excess of $280 million. Conclusions: If preliminary findings suggesting the effectiveness of MTX as an alternative therapy for EP are confirmed, appropriate use of MTX will not only reduce morbidity but also the substantial cost.

KW - cost

KW - Ectopic pregnancy

KW - methotrexate

UR - http://www.scopus.com/inward/record.url?scp=0027433332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027433332&partnerID=8YFLogxK

M3 - Article

C2 - 8243700

AN - SCOPUS:0027433332

VL - 60

SP - 963

EP - 969

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 6

ER -